The BUMN vaccine is the result of a global collaboration between Bio Farma and Baylor College of Medicine USA.
The holding parent of Pharmaceutical BUMN, Bio Farma, will soon carry out Phase 3 Clinical Trial of BUMN Vaccines for the prevention of Covid-19 in early June 2022. The declaration was marked by a Kick-off which was held at the Faculty of Medicine, Diponegoro University (FK UNDIP) on Thursday (9/09). 6/2022).
The kick-off activity was attended by SOE Minister Erick Thohir, RI Deputy Minister of Health Dante Saksono Harbuwono, Head of BPOM Penny Lukito, UNDIP Chancellor represented by Vice Chancellor IV, Prof. Dr. Ir. Ambariyanto, M.Sc, Dean of FK UNDIP Dr. dr. Dwi Pudjonarko, M.Kes., Sp.S(K), President Director of Bio Farma, Honesti Basyir along with the Board of Executives of Bio Farma and President Commissioner of Bio Farma Tanri Abeng.
The BUMN vaccine is the result of a global collaboration between Bio Farma and Baylor College of Medicine USA which has been registered in the WHO Covid-19 vaccine candidate development stage since last June 2021.
The BUMN vaccine uses Recombinant Protein Subunit (Protein Receptor Binding Domain / RBD) technology, which is made in Indonesia and will be used as a primary vaccine after obtaining an Emergency Use Authorization (EUA) from the POM at the end of July 2022.
The implementation of this phase 3 clinical trial was carried out after Bio Farma obtained the Approval for the Implementation of Clinical Trials (PPUK) for the Phase 3 Clinical Trial, which was signed by the Head of the POM RI Penny K Lukito, on June 6, 2022.
In addition to being carried out in Semarang, Phase 3 Clinical Trials were also carried out in the City of Jakarta in collaboration with the Faculty of Medicine at the University of Indonesia, in Padang in collaboration with the Faculty of Medicine at Andalas University, and Makassar in collaboration with the Faculty of Medicine at Hasanuddin University. (antara, we)
